Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: results of a controlled study of etilefrine versus placebo
A Moya,
G Permanyer-Miralda,
J Sagrista-Sauleda,
X Carne,
T Rius,
L Mont,
and
J Soler-Soler
Servei de Cardiologia, Hospital General Universitari Vall d'Hebron, Barcelona, Spain.
OBJECTIVES. This study assessed the efficacy of oral etilefrine (10 mg three times a day) in preventing a positive response to head-up tilt testing. BACKGROUND. Previous reports have suggested that oral etilefrine can be effective either in preventing a positive response to head-up tilt testing or in reducing syncopal recurrences in patients with vasovagal syncope. Up to now most studies assessing drug therapy in these patients have been uncontrolled. METHODS. This was a randomized double-blind crossover study of etilefrine versus placebo in 30 consecutive patients with syncope and a baseline positive head-up tilt test. After the first test, patients had no treatment for 3 days and were randomized to receive etilefrine or placebo for 4 additional days. They underwent tilt testing under treatment and again after 3 days of washout; they then received the alternative treatment for 4 days, and a third test was performed. RESULTS. Head-up tilt test results were negative in 13 (43%) patients with etilefrine and 15 (50%) with placebo (p = NS). Therefore, the statistical power of the study was only 10%. The rate of positive responses decreased with repeated testing irrespective of the assigned treatment: A positive response was obtained during the second head-up tilt test in 20 patients (10 with placebo, 10 with etilefrine) but in only 12 during the third (7 with etilefrine, 5 with placebo) (p < 0.05). CONCLUSIONS. Oral etilefrine (10 mg three times a day) was not superior to placebo in preventing a positive response to head-up tilt testing. Despite a low statistical power, the high rate of negative response with placebo (50%) suggests that controlled trials are needed to assess the real efficacy of any treatment in patients with vasovagal syncope.
This article has been cited by other articles:

|
 |

|
 |
 
M. P. Tan, J. L. Newton, T. J. Chadwick, J. C. Gray, S. Nath, and S. W. Parry
Home orthostatic training in vasovagal syncope modifies autonomic tone: results of a randomized, placebo-controlled pilot study
Europace,
November 17, 2009;
(2009)
eup368v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Developed in collaboration with, European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), and Heart Rhythm Society (HRS), Endorsed by the following societies, European Society of Emergency Medicine (EuSEM), European Federation of Internal Medicine (EFIM), European Union Geriatric Medicine Society (EUGMS), American Geriatrics Society (AGS), European Neurological Society (ENS), et al.
Guidelines for the diagnosis and management of syncope (version 2009): The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC)
Eur. Heart J.,
November 1, 2009;
30(21):
2631 - 2671.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. P. Tan and S. W. Parry
Reply.
J. Am. Coll. Cardiol.,
June 17, 2008;
51(24):
2372 - 2373.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Petkar and A. Fitzpatrick
Tilt-table testing: transient loss of consciousness discriminator or epiphenomenon?
Europace,
June 1, 2008;
10(6):
747 - 750.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Brignole, F. Giada, A. Raviele, and J. J. Blanc
Pacing for syncope: what role? which perspective?
Eur. Heart J. Suppl.,
December 1, 2007;
9(suppl_I):
I37 - I43.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al.
Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association
Europace,
October 1, 2007;
9(10):
959 - 998.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Authors/Task Force Members, P. E. Vardas, A. Auricchio, J.-J. Blanc, J.-C. Daubert, H. Drexler, H. Ector, M. Gasparini, C. Linde, F. B. Morgado, et al.
Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in Collaboration with the European Heart Rhythm Association
Eur. Heart J.,
September 2, 2007;
28(18):
2256 - 2295.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. N. Theodorakis, D. Leftheriotis, E. G. Livanis, P. Flevari, G. Karabela, N. Aggelopoulou, and D. Th. Kremastinos
Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study.
Europace,
March 1, 2006;
8(3):
193 - 198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Guidelines on Management (diagnosis and treatment) of syncope - update 2004: The Task Force on Syncope, European Society of Cardiology
Europace,
January 1, 2004;
6(6):
467 - 537.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Sagrista-Sauleda, B. Romero, G. Permanyer-Miralda, A. Moya, and J. Soler-Soler
Reproducibility of sequential head-up tilt testing in patients with recent syncope, normal ECG and no structural heart disease
Eur. Heart J.,
November 1, 2002;
23(21):
1706 - 1713.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Flevari, E. G. Livanis, G. N. Theodorakis, E. Zarvalis, T. Mesiskli, and D. T. h Kremastinos
Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being
J. Am. Coll. Cardiol.,
August 7, 2002;
40(3):
499 - 504.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Kouakam, G. Vaksmann, E. Pachy, D. Lacroix, C. Rey, and S. Kacet
Long-term follow-up of children and adolescents with syncope; predictor of syncope recurrence
Eur. Heart J.,
September 1, 2001;
22(17):
1618 - 1625.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
Task Force on Syncope, European Society of Cardiol, M Brignole, P Alboni, D Benditt, L Bergfeldt, J.J Blanc, P.E Bloch Thomsen, J.G van Dijk, A Fitzpatrick, S Hohnloser, et al.
Guidelines on management (diagnosis and treatment) of syncope
Eur. Heart J.,
August 1, 2001;
22(15):
1256 - 1306.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. H. Madrid, J. Ortega, J. G. Rebollo, J. G. Manzano, J. G. Segovia, A. Sanchez, G. Pena, and C. Moro
Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study
J. Am. Coll. Cardiol.,
February 1, 2001;
37(2):
554 - 559.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Sheldon and S. Rose
Components of clinical trials for vasovagal syncope
Europace,
January 1, 2001;
3(3):
233 - 240.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Raviele, F. Giada, R. Sutton, P. Alboni, M. Brignole, A. Del Rosso, E. di Girolamo, R. Luise, and C. Menozzi
The Vasovagal Syncope and Pacing (Synpace) trial: rationale and study design
Europace,
January 1, 2001;
3(4):
336 - 341.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
S.W. Parry and R.A. Kenny
The management of vasovagal syncope
QJM,
December 1, 1999;
92(12):
697 - 705.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. G. Benditt, G. J. Fahy, K. G. Lurie, S. Sakaguchi, W. Fabian, and N. Samniah
Pharmacotherapy of Neurally Mediated Syncope
Circulation,
September 14, 1999;
100(11):
1242 - 1248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Raviele, M. Brignole, R. Sutton, P. Alboni, P. Giani, C. Menozzi, and A. Moya
Effect of Etilefrine in Preventing Syncopal Recurrence in Patients With Vasovagal Syncope : A Double-Blind, Randomized, Placebo-Controlled Trial
Circulation,
March 23, 1999;
99(11):
1452 - 1457.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Sagrista-Sauleda, B. Romero, G. Permanyer-Miralda, A. Moya, T. Rius-Gelabert, L. Mont Girbau, and J. Soler-Soler
Clinical usefulness of head-up tilt test in patients with syncope and intraventricular conduction defect
Europace,
January 1, 1999;
1(1):
63 - 68.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Flammang, M. Antiel, T. Church, A. Chassing, D. Hamani, E. Donal, and M. Waynberger
Is a pacemaker indicated for vasovagal patients with severe cardioinhibitory reflex as identified by the ATP test?: A preliminary randomized trial
Europace,
January 1, 1999;
1(2):
140 - 145.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
C R Ward, J C Gray, J J Gilroy, and R A Kenny
Midodrine: a role in the management of neurocardiogenic syncope
Heart,
January 1, 1998;
79(1):
45 - 49.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|